Kidney Transplant Rejection Market To Observe Growth At A CAGR Of 4.9% During The Forecast ...
The kidney transplant rejection prophylaxis market is projected to experience steady growth, driven by the introduction of innovative therapi ...
Travere Therapeutics, Inc.: Travere Therapeutics to Submit sNDA for FILSPARI (sparsentan ...
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25 If approved, FILSPARI could be the first and only approved medicine indicated ...
Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS
Company completed Type C meeting with FDA, aligning on its plan to submit an sNDA; submission expected around end of 1Q25If approved, FILSPARI ...
How Thomas Edison Jr. Shamed the Family Name
It was sold by the Thomas A. Edison Jr. Chemical Company, an outfit ostensibly owned by the son of famed inventor Thomas Edison. The family name had become synonymous with innovation; most people ...